valneva’s wild stockprice rise continued on monday after the french biotech said its coronavirus vaccine candidate outperformed astrazeneca’s in a trial valneva frvla valn shares rose as much as 42 after it said a phase 3 trial showed its vaccine candidate vla2001 outperformed astrazeneca’s ukazn in a trial of 4012 people with a significantly more favorable tolerability profile valneva said its vaccine produced more neutralized antibodies and there was a complete absence of any severe covid19 cases even with monday’s gain the stock is still trading below its highs of september when the uk government terminated a supply agreement valneva said it will continue to work closely with the uk medicines and healthcare products regulatory agency to complete its rolling submission for approal and is preparing to start the process to get conditional approval with the european medicines agency european stocks more broadly traded lower after china reported slowerthanforecast thirdquarter growth of 49 yearoveryear luxurygoods makers kering frker and lvmh moet hennessy louis vuitton frmc declined after the disappointing chinese numbers sending the stoxx europe 600 xxsxxp down 04 to 46765 of the major regional indexes the german dax dxdax declined 04 the french cac 40 frpx1 declined 07 and the uk ftse 100 ukukx declined 02 one advancer was thg ukthg rising 7 after the softbankbacked retailer said it will remove its special share rights thg shares are now up 19 from last week but down 60 for the year on concerns that softbank jp9984 won’t trigger an option to buy a thg division the yield on the 2year gilt bxtmbmkgb02y jumped 14 basis points to 072 after bank of england gov andrew bailey said on sunday the central bank will have to act to curb inflationary pressure